SCHEMBL30108035

SCHEMBL30108035

Nc1nc(-c2ccoc2)cc(-n2nnc3cc(O)ccc32)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NT5E P21589 3/20 0.43
ADORA2A P29274 2/20 0.33
DHFR P00374 1/20 0.33
FYN P06241 1/20 0.32
KDM4E B2RXH2 1/20 0.32
NPC1 O15118 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
CDC7 O00311 2/20 0.32
CDK2 P24941 2/20 0.32
PELI1 Q96FA3 1/20 0.32
HRH1 P35367 1/20 0.31
HRH4 Q9H3N8 1/20 0.31
HRH3 Q9Y5N1 1/20 0.31
ADORA3 P0DMS8 1/20 0.31
ADORA2B P29275 1/20 0.31
HSD17B10 Q99714 2/20 0.31
KDM5B Q9UGL1 1/20 0.31
ALDH1A1 P00352 1/20 0.31
CYP1A2 P05177 1/20 0.31
ALOX15 P16050 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30108001 0.82 KDM4E (0.33) KDM4ENPC1L3MBTL1CDC7CDK2
SCHEMBL30107959 0.80 KDM4E (0.44) ADORA2AKDM4EADORA3ADORA2BHSD17B10
SCHEMBL30107988 0.73 TSHR (0.33) ADORA2AKDM4ENPC1L3MBTL1CDC7
SCHEMBL30108015 0.71 HRH3 (0.46) KDM4ENPC1L3MBTL1CDK2HRH4
SCHEMBL30107978 0.71 KDM4E (0.44) NT5EADORA2AKDM4EADORA3ADORA2B
SCHEMBL30107992 0.71 ADORA2A (0.37) ADORA2AKDM4ENPC1L3MBTL1ADORA3
SCHEMBL30107957 0.70 HRH4 (0.32) KDM4ENPC1L3MBTL1HRH4HRH3
SCHEMBL30108056 0.70 ADORA2A (0.47) ADORA2AADORA2B
SCHEMBL30108014 0.67 KDM4E (0.42) ADORA2AKDM4EADORA3ADORA2BHSD17B10
SCHEMBL30108012 0.65 TSHR (0.58) ADORA2AKDM4ENPC1L3MBTL1ADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022203399-A1 ADENOSINE A2A RECEPTOR ANTAGONIST AND USE THEREOF 주식회사 스탠다임 2022-09-29 WO disclosed